Binita Chakraborty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Binita Chakraborty has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Donald Patrick McDonnell
Duke University School of Medicine, Durham, North Carolina
47 shared publications - Ching-Yi Chang
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina, USA
34 shared publications - Corinne Haines
Nationwide Children’s Hospital 1 Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute Columbus, Ohio
34 shared publications - Sandeep Artham
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina, USA
20 shared publications - Debarati Mukherjee
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina
19 shared publications - Frank H. Lau
Department of Surgery, Section of Plastic & Reconstructive Surgery, Louisiana State University Health Sciences Center, New Orleans, Louisiana
19 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Purpose:In advanced estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative breast cancer, the combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard of care for treatment in the first-line setting. Although CDK4/6is were initially developed to induce cell-cycle arrest, it is evident that CDK4/6is also have the potential to regulate the tumor immune microenvironment. In this study, we characterize the baseline immune landscape and the immunomodulatory effects of abemaciclib and ET in advanced breast cancer tumors. Experimental Design:We used single-cell RNA sequencing of CD45-enriched cells to investigate the effect of the CDK4/6i, abemaciclib, and ET on the transcriptome of immune cell populations in 13 matched-pair advanced and metastatic estrogen receptor–positive/HER2− breast tumor biopsies. We tested the association of immune cell population gene signatures with survival in publicly available datasets. Results:We profiled 170,798 cells from bone, breast, lymph node, and liver biopsies. We found that the expression of genes associated with interferon response are downregulated in many T-cell populations. The expression of genes associated with antigen presentation was upregulated in tumor-associated macrophages (TAM) and dendritic cells after treatment. The relative proportion of TREM2+ TAMs decreases after treatment with abemaciclib and ET in late progressors, and lower expression of the TREM2+ TAM signature is associated with improved overall survival (OS) in patients with breast cancer. Conclusions:Our data reveal heterogeneous lymphoid and myeloid subpopulations in advanced and metastatic breast tumors that are associated with late progression on abemaciclib and ET and OS in patients with breast cancer.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Purpose:In advanced estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative breast cancer, the combination of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard of care for treatment in the first-line setting. Although CDK4/6is were initially developed to induce cell-cycle arrest, it is evident that CDK4/6is also have the potential to regulate the tumor immune microenvironment. In this study, we characterize the baseline immune landscape and the immunomodulatory effects of abemaciclib and ET in advanced breast cancer tumors. Experimental Design:We used single-cell RNA sequencing of CD45-enriched cells to investigate the effect of the CDK4/6i, abemaciclib, and ET on the transcriptome of immune cell populations in 13 matched-pair advanced and metastatic estrogen receptor–positive/HER2− breast tumor biopsies. We tested the association of immune cell population gene signatures with survival in publicly available datasets. Results:We profiled 170,798 cells from bone, breast, lymph node, and liver biopsies. We found that the expression of genes associated with interferon response are downregulated in many T-cell populations. The expression of genes associated with antigen presentation was upregulated in tumor-associated macrophages (TAM) and dendritic cells after treatment. The relative proportion of TREM2+ TAMs decreases after treatment with abemaciclib and ET in late progressors, and lower expression of the TREM2+ TAM signature is associated with improved overall survival (OS) in patients with breast cancer. Conclusions:Our data reveal heterogeneous lymphoid and myeloid subpopulations in advanced and metastatic breast tumors that are associated with late progression on abemaciclib and ET and OS in patients with breast cancer.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S8. Heatmap depicting gene set enrichment results identified from genes that were differentially expressed between T1 and T2 for each myeloid cluster in each response group. Color indicates normalized enrichment score where a positive value indicates the pathway was more highly expressed at T2. * FDR £ 0.05.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S8. Heatmap depicting gene set enrichment results identified from genes that were differentially expressed between T1 and T2 for each myeloid cluster in each response group. Color indicates normalized enrichment score where a positive value indicates the pathway was more highly expressed at T2. * FDR £ 0.05.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S4. A) Box plot of IFNG expression at T1 and T2 for each T cell cluster grouped by response. Median expression is indicated by green line. Statistical significance determined by two-way ANOVA with post-hoc Tukey-HSD test. *p.adjust £ 0.05. B) Heatmap depicting gene set enrichment results identified from genes that were differentially expressed between T1 and T2 for each lymphoid cluster in each response group. Color indicates normalized enrichment score where a positive value indicates the pathway was more highly expressed at T2. * FDR £ 0.05.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S4. A) Box plot of IFNG expression at T1 and T2 for each T cell cluster grouped by response. Median expression is indicated by green line. Statistical significance determined by two-way ANOVA with post-hoc Tukey-HSD test. *p.adjust £ 0.05. B) Heatmap depicting gene set enrichment results identified from genes that were differentially expressed between T1 and T2 for each lymphoid cluster in each response group. Color indicates normalized enrichment score where a positive value indicates the pathway was more highly expressed at T2. * FDR £ 0.05.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S2-S12 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Table S2. Patient characteristics and number of cells analyzed. Supplementary Table S3. Marker genes for each cluster Supplementary Table S4. ANOVA with Tukey HSD multiple test correction results for cell type population size comparisons between response groups. Supplementary Table S5. ANOVA with Tukey HSD multiple test correction results for cell type population size comparisons between metastatic sites. Supplementary Table S6. Top 50 Marker genes for each lymphoid cluster Supplementary Table S7. Genes used for pathway signatures retrieved from MSigDB. Supplementary Table S8. Genes differentially expressed between lymphoid clusters between T2 and T1 for each response group. Positive log2FC indicates gene is more highly expressed at T2. Supplementary Table S9. Top 50 Marker genes for each myeloid cluster Supplementary Table S10. Genes differentially expressed between myeloid clusters between T2 and T1 for each response group. Positive log2FC indicates gene is more highly expressed at T2. Supplementary Table S11. Genes differentially expressed between myeloid clusters 1, 5, and 7. Supplementary Table S12. Genes used for survival analyses. Genes were selected by using a max pvalue cutoff of 0.05.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S2-S12 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Table S2. Patient characteristics and number of cells analyzed. Supplementary Table S3. Marker genes for each cluster Supplementary Table S4. ANOVA with Tukey HSD multiple test correction results for cell type population size comparisons between response groups. Supplementary Table S5. ANOVA with Tukey HSD multiple test correction results for cell type population size comparisons between metastatic sites. Supplementary Table S6. Top 50 Marker genes for each lymphoid cluster Supplementary Table S7. Genes used for pathway signatures retrieved from MSigDB. Supplementary Table S8. Genes differentially expressed between lymphoid clusters between T2 and T1 for each response group. Positive log2FC indicates gene is more highly expressed at T2. Supplementary Table S9. Top 50 Marker genes for each myeloid cluster Supplementary Table S10. Genes differentially expressed between myeloid clusters between T2 and T1 for each response group. Positive log2FC indicates gene is more highly expressed at T2. Supplementary Table S11. Genes differentially expressed between myeloid clusters 1, 5, and 7. Supplementary Table S12. Genes used for survival analyses. Genes were selected by using a max pvalue cutoff of 0.05.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S6. A) UMAP visualization of myeloid cell type markers for macrophages (CD68), M2-like macrophages (CD163), antigen-presenting cells (HLA-DRA), monocytes (CD14), dendritic cells (CD1C), and mast cells (KIT). B) Relative proportions of myeloid clusters per patient per timepoint per metastasis site. C) Relative proportions of myeloid clusters per patient per timepoint per response group.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S6. A) UMAP visualization of myeloid cell type markers for macrophages (CD68), M2-like macrophages (CD163), antigen-presenting cells (HLA-DRA), monocytes (CD14), dendritic cells (CD1C), and mast cells (KIT). B) Relative proportions of myeloid clusters per patient per timepoint per metastasis site. C) Relative proportions of myeloid clusters per patient per timepoint per response group.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S7. A) UMAP visualization of G1/S CDKs, CDK4, CDK6, and CDK2. B) C) Heatmap depicting differential expression of CDK4/6 target genes and proliferation markers in each cluster grouped by response. Color indicates average log2FC where a positive value indicates the gene was more highly expressed at T2. * FDR £ 0.05. UMAP visualization of hormone receptor genes, ESR1, ESR2, GPER1, PGR and AR and ER target genes, GREB1 and TFF1 in myeloid clusters split by timepoint.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S7. A) UMAP visualization of G1/S CDKs, CDK4, CDK6, and CDK2. B) C) Heatmap depicting differential expression of CDK4/6 target genes and proliferation markers in each cluster grouped by response. Color indicates average log2FC where a positive value indicates the gene was more highly expressed at T2. * FDR £ 0.05. UMAP visualization of hormone receptor genes, ESR1, ESR2, GPER1, PGR and AR and ER target genes, GREB1 and TFF1 in myeloid clusters split by timepoint.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Table S1. Representativeness of Study Participants.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Table S1. Representativeness of Study Participants.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S2. A) UMAP visualization of lymphoid marker genes. B) Relative proportions of lymphoid clusters per patient per timepoint per metastasis site. C) Relative proportions of lymphoid clusters per patient per timepoint per response group.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S2. A) UMAP visualization of lymphoid marker genes. B) Relative proportions of lymphoid clusters per patient per timepoint per metastasis site. C) Relative proportions of lymphoid clusters per patient per timepoint per response group.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S3. A) UMAP visualization of G1/S CDKs, CDK4, CDK6, and CDK2. B) C) Heatmap depicting differential expression of CDK4/6 target genes and proliferation markers in each cluster grouped by response. Color indicates average log2FC where a positive value indicates the gene was more highly expressed at T2. * FDR £ 0.05. UMAP visualization of hormone receptor genes, ESR1, ESR2, GPER1, PGR and AR and ER target genes, GREB1 and TFF1 in lymphoid clusters split by timepoint.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S3. A) UMAP visualization of G1/S CDKs, CDK4, CDK6, and CDK2. B) C) Heatmap depicting differential expression of CDK4/6 target genes and proliferation markers in each cluster grouped by response. Color indicates average log2FC where a positive value indicates the gene was more highly expressed at T2. * FDR £ 0.05. UMAP visualization of hormone receptor genes, ESR1, ESR2, GPER1, PGR and AR and ER target genes, GREB1 and TFF1 in lymphoid clusters split by timepoint.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S9. A) Heatmap of top 20 differentially expressed genes between myeloid cluster 0: APOC1 TAMs, myeloid cluster 5: TREM2 TAMs, and cluster 7: APOC2 TAMs. B) Heatmap of top 20 enriched pathways derived from genes identified as differentially expressed between myeloid cluster 0: APOC1 TAMs, myeloid cluster 5: TREM2 TAMs, and cluster 7: APOC2 TAMs. *p_val_adj £ 0.05.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor–Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy
Supplementary Fig. S9. A) Heatmap of top 20 differentially expressed genes between myeloid cluster 0: APOC1 TAMs, myeloid cluster 5: TREM2 TAMs, and cluster 7: APOC2 TAMs. B) Heatmap of top 20 enriched pathways derived from genes identified as differentially expressed between myeloid cluster 0: APOC1 TAMs, myeloid cluster 5: TREM2 TAMs, and cluster 7: APOC2 TAMs. *p_val_adj £ 0.05.